Lakefront Biotherapeutics NV repurchased 107,804 shares between October 12 and October 16, 2026, for a total of €2,854,365.69 at an average price of €26.48 per share. The purchases were made through a discretionary mandate to an independent financial intermediary.
As of market close on October 16, 2026, Lakefront held 1,985,157 of its own ordinary shares. The repurchase program announced on June 9, 2026, was fully completed.
Lakefront Biotherapeutics NV completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV. The agreement terms include an upfront €8 million payment, potential milestone payments of up to $230 million, and a low-single-digit royalty to Lakefront.
The transferred preclinical assets comprise multi-targeting and armed CAR-T constructs designed to improve potency and persistence and prevent cancer treatment resistance in hematological and solid tumors of high unmet need. Armed Cell will independently advance the programs.
Lakefront Biotherapeutics NV repurchased 126,322 ordinary shares between October 5 and October 9, 2026, within the repurchase program announced June 9, 2026. The average price paid was €26.26 per share, for a total of €3,317,407.94; reported purchase prices ranged from €25.78 to €26.78 per share.
Lakefront Biotherapeutics NV received a transparency notification from Bank of America Corporation, which reported crossing below the 10% threshold of Lakefront voting rights on October 2, 2026, following a disposal of voting rights and equivalent financial instruments. On that date, Bank of America Corporation, taking account of its affiliates, held 254,604 voting rights and 5,371,394 equivalent financial instruments, together representing 8.54% of Lakefront’s 65,897,071 outstanding shares. The notification reports that direct voting rights represented 0.39% and equivalent financial instruments represented 8.15%.
Lakefront Biotherapeutics NV repurchased 117,437 shares between September 28, 2026, and October 2, 2026, within the repurchase program announced on June 9, 2026. The purchases were made through a discretionary mandate to an independent financial intermediary, at an average price of €25.99 per share and for a reported total of €3,051,866.51.
As of market close on October 2, 2026, Lakefront held 1,751,031 of its own ordinary shares.
Lakefront Biotherapeutics NV (LKFT) repurchased 106,060 shares between September 21 and September 25, 2026, under the repurchase program announced June 9, 2026. The purchases were executed through a discretionary mandate to an independent financial intermediary. Lakefront paid €2,795,740.67 in total, at an average price of €26.36 per share; the reported prices ranged from €24.68 to €28.34.
As of market close on September 25, 2026, Lakefront held 1,633,594 of its own ordinary shares.
Lakefront Biotherapeutics NV repurchased 108,679 ordinary shares between September 14 and September 18, 2026, under the repurchase program announced June 9, 2026. The purchases were made through a discretionary mandate to an independent financial intermediary, at an average price of €24.00 per share and a reported total of €2,608,832.08.
As of market close on September 18, 2026, Lakefront held 1,527,534 of its own ordinary shares.
Lakefront Biotherapeutics NV (LKFT) reports that, under its share repurchase program announced on June 9, 2026, it bought back 125,517 ordinary shares between September 7 and September 11, 2026 through an independent financial intermediary across several European trading venues.
The repurchases were executed at an average price of €23.95 per share, for a total consideration of €3,005,545.12, with prices ranging from €23.20 to €24.56. As of market close on September 11, 2026, Lakefront held 1,418,855 of its own ordinary shares.
Lakefront Biotherapeutics NV (LKFT) reported that it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The company plans to host a fireside chat at 5:35 p.m. ET on September 15, 2026, with a live webcast and a replay available on its investor website for up to 90 days.
The company highlights a clinical-stage portfolio in immunology and inflammation, led by gamgertamig, described as a potential first‑in‑class and best‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases.
Lakefront Biotherapeutics NV (LKFT) reports progress under its share repurchase program announced on June 9, 2026. Between August 31 and September 4, 2026, the company repurchased 132,014 ordinary shares through an independent financial intermediary for a total of €3,279,463.42, at an average price of €24.84 per share and within a price range of €24.44–€25.38.
As of market close on September 4, 2026, Lakefront holds 1,293,338 of its own ordinary shares. The company reiterates that plans to repurchase its ordinary shares involve forward-looking statements subject to the risks and uncertainties described in its SEC reports.